Mouse models of ERMS contain combinations of activating mutations in proto oncogenes such as HGF/SF, HER2-neu, and Kras and inactivating mutations in tumor suppressors such as Ink4a/Arf or Trp53 [11,12,13,14,15,16,17]. This evidence concerns the gene HGF and embryonal rhabdomyosarcoma.